You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

Guidelines & Advice
About Guidelines Email Guidelines Team

Sunitinib Malate for Gastrointestinal Stromal Tumour (GIST) in Imatinib Mesylate Resistant Patients

Version: 2 ID: 11-8 Oct 2015
Type of Content: Guidelines & Advice, Clinical
Document Status: Archived
Authors:
Sarcoma Disease Site Group